Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Very low-density lipoprotein Stories

2014-03-31 12:28:11

- Reductions of up to 64 percent in triglycerides achieved CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIII(Rx) in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIII(Rx) achieved average reductions of up to 71 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides, and...

2013-11-18 20:44:39

Seth S. Martin, M.D., of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, and colleagues developed a method for estimating low-density lipoprotein cholesterol (LDL-C) levels that is more accurate than the standard measure. Low-density lipoprotein cholesterol is the primary target for treatment in national and international clinical practice guidelines. Conventionally, LDL-C is estimated by the Friedewald equation, which estimates LDL-C as (total...

2013-09-21 12:22:07

Reductions of more than 1,500 mg/dL in triglycerides observed CARLSBAD, Calif., Sept. 21, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced data from a Phase 2 study of ISIS-APOCIII(Rx) as a monotherapy in patients with familial chylomicronemia syndrome, or FCS. FCS is a rare orphan disease characterized by severely high triglyceride levels that affects an estimated 3,000 to 5,000 patients worldwide. These data were presented today by Dr. Daniel Gaudet at...

2013-08-31 08:20:18

Statistically Significant Reductions of up to 75 percent in Triglycerides and up to 79 percent in ApoC-III CARLSBAD, Calif., Aug. 31, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced interim data from an ongoing Phase 2 study of ISIS-APOCIII(Rx) as a monotherapy in patients with very high to severely high triglycerides. These data were presented today by Dr. Daniel Gaudet at a PACE session occurring concurrently with the European Society of Cardiology in...

2013-07-22 08:27:19

Reductions of up to 64 percent in Triglycerides Achieved CARLSBAD, Calif., July 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced data from a Phase 2 study of ISIS-APOCIII(Rx) in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIII(Rx) experienced reductions of up to 70 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides. In addition, patients...

2012-05-31 02:25:02

SCOTTSDALE, Ariz., May 31, 2012 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE:LLY) today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO® (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles...

2012-05-24 21:06:36

Physical activity shows small benefit on triglyceride levels New research found that moderate exercise does not improve lipoprotein concentrations in obese patients with non alcoholic fatty liver disease (NAFLD). Results published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, report that moderate physical activity produces only a small decrease in triglyceride and alanine transaminase (ALT) levels. Obesity is a rampant health...

2011-09-08 15:21:00

BETHESDA, Md., Sept. 8, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) - an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies - today announced that its drug candidate, SPX-106, achieved statistically significant reductions in VLDL and LDL cholesterol when administered in combination with Dtagatose (SPX-106T) for...

2011-07-22 01:46:28

Obese people with high levels of abdominal fat and liver fat may face increased risks for heart disease and other serious health problems, according to research published in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association. Obesity is commonly associated with heart disease risk and problems called cardiometabolic abnormalities, including insulin resistance, type 2 diabetes, cholesterol disorders, hypertension and gout. Researchers in Sweden and...

0f2c9c0e8e62f180b82af9edac1c413a
2010-08-05 06:05:00

Researchers have uncovered 95 genes that are believed to affect blood cholesterol, including a few that are affected by drugs and others that might be the basis of new drugs. The findings show that regulating cholesterol levels is even more complex than many people knew but also point to some short-cuts to prevent heart disease. The variations account for a quarter to a third of the inherited variation in cholesterol levels and triglycerides, the researchers said. "These results help refine...